Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma
Ann‐Lii Cheng, Chiun Hsu, Stephen L. Chan, et al.
Journal of Hepatology (2020) Vol. 72, Iss. 2, pp. 307-319
Open Access | Times Cited: 424

Showing 1-25 of 424 citing articles:

Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma
Yun‐Fan Sun, Liang Wu, Yu Zhong, et al.
Cell (2020) Vol. 184, Iss. 2, pp. 404-421.e16
Open Access | Times Cited: 614
Evolving therapeutic landscape of advanced hepatocellular carcinoma
Chen Yang, Hailin Zhang, Linmeng Zhang, et al.
Nature Reviews Gastroenterology & Hepatology (2022) Vol. 20, Iss. 4, pp. 203-222
Closed Access | Times Cited: 417
Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy
Yao Liu, Zhenzhen Xun, Kun Ma, et al.
Journal of Hepatology (2023) Vol. 78, Iss. 4, pp. 770-782
Closed Access | Times Cited: 295
Immunobiology and immunotherapy of HCC: spotlight on innate and innate-like immune cells
Benjamin Ruf, Bernd Heinrich, Tim F. Greten
Cellular and Molecular Immunology (2020) Vol. 18, Iss. 1, pp. 112-127
Open Access | Times Cited: 228
Tumor‐associated macrophages in liver cancer: From mechanisms to therapy
Kun Cheng, Ning Cai, Jinghan Zhu, et al.
Cancer Communications (2022) Vol. 42, Iss. 11, pp. 1112-1140
Open Access | Times Cited: 204
Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities
Stephen P. Hack, Andrew X. Zhu, Yulei Wang
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 200
Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma
Masatoshi Kudo
Cancers (2020) Vol. 12, Iss. 5, pp. 1089-1089
Open Access | Times Cited: 160
Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis
Matteo Santoni, Alessandro Rizzo, Jakub Kucharz, et al.
Cancer Immunology Immunotherapy (2023) Vol. 72, Iss. 6, pp. 1365-1379
Closed Access | Times Cited: 135
Transarterial Chemoembolization Combined With Lenvatinib Plus PD-1 Inhibitor for Advanced Hepatocellular Carcinoma: A Retrospective Cohort Study
Mingyue Cai, Wensou Huang, Jingjun Huang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 128
Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma
Rui Xing, Jinping Gao, Qi Cui, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 123
GOLM1 exacerbates CD8+ T cell suppression in hepatocellular carcinoma by promoting exosomal PD-L1 transport into tumor-associated macrophages
Jinhong Chen, Zhifei Lin, Lu Liu, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 118
Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects
Zhuoyan Liu, Xuan Liu, Jiaxin Liang, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 112
Experience with regorafenib in the treatment of hepatocellular carcinoma
Alessandro Granito, A. Forgione, Sara Marinelli, et al.
Therapeutic Advances in Gastroenterology (2021) Vol. 14
Open Access | Times Cited: 109
Universal immunotherapeutic strategy for hepatocellular carcinoma with exosome vaccines that engage adaptive and innate immune responses
Bingfeng Zuo, Yang Zhang, Kangjie Zhao, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 98
TREM2+ macrophages suppress CD8+ T-cell infiltration after transarterial chemoembolisation in hepatocellular carcinoma
Jizhou Tan, Wenzhe Fan, Ting Liu, et al.
Journal of Hepatology (2023) Vol. 79, Iss. 1, pp. 126-140
Closed Access | Times Cited: 90
Small molecule inhibitors targeting the cancers
Guihong Liu, Tao Chen, Xin Zhang, et al.
MedComm (2022) Vol. 3, Iss. 4
Open Access | Times Cited: 87
Disulfidptosis classification of hepatocellular carcinoma reveals correlation with clinical prognosis and immune profile
Tian-bing Wang, Kai Guo, Di Zhang, et al.
International Immunopharmacology (2023) Vol. 120, pp. 110368-110368
Open Access | Times Cited: 87
Which role for predictors of response to immune checkpoint inhibitors in hepatocellular carcinoma?
Alessandro Rizzo, Antonio Cusmai, Gennaro Gadaleta‐Caldarola, et al.
Expert Review of Gastroenterology & Hepatology (2022) Vol. 16, Iss. 4, pp. 333-339
Closed Access | Times Cited: 79
Cancer‐associated fibroblast‐derived secreted phosphoprotein 1 contributes to resistance of hepatocellular carcinoma to sorafenib and lenvatinib
Jung Woo Eun, Jung Hwan Yoon, Hye Ri Ahn, et al.
Cancer Communications (2023) Vol. 43, Iss. 4, pp. 455-479
Open Access | Times Cited: 79
The pyroptosis-related gene signature predicts prognosis and indicates immune activity in hepatocellular carcinoma
Min Deng, Shiquan Sun, Rongce Zhao, et al.
Molecular Medicine (2022) Vol. 28, Iss. 1
Open Access | Times Cited: 68
Immunotherapy for hepatocellular carcinoma: Current status and future perspectives
Deepa S. Mandlik, Satish K. Mandlik, Heena B Choudhary
World Journal of Gastroenterology (2023) Vol. 29, Iss. 6, pp. 1054-1075
Open Access | Times Cited: 58
Immune-checkpoint inhibitor resistance in cancer treatment: Current progress and future directions
Chenyue Zhang, Chenxing Zhang, Haiyong Wang
Cancer Letters (2023) Vol. 562, pp. 216182-216182
Closed Access | Times Cited: 53
Prognostic signatures of sphingolipids: Understanding the immune landscape and predictive role in immunotherapy response and outcomes of hepatocellular carcinoma
Xin Zhang, Jinke Zhuge, Jinhui Liu, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 42
TET2-mediated tumor cGAS triggers endothelial STING activation to regulate vasculature remodeling and anti-tumor immunity in liver cancer
Hongwei Lv, Qianni Zong, Cian Chen, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 26
Regorafenib enhances antitumor immunity via inhibition of p38 kinase/Creb1/Klf4 axis in tumor-associated macrophages
Da‐Liang Ou, Chia-Wei Chen, Chia‐Lang Hsu, et al.
Journal for ImmunoTherapy of Cancer (2021) Vol. 9, Iss. 3, pp. e001657-e001657
Open Access | Times Cited: 100
Page 1 - Next Page

Scroll to top